CS
MYGN icon

Credit Suisse’s Myriad Genetics MYGN Stock Holding History

Credit Suisse’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-160,000
Closed -$3.36M – 4796
2013
Q4 		$3.36M Buy
+160,000
New +$4.05M ﹤0.01% 2190

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Credit Suisse's MYGN Position: Q1 2024 in Review

Credit Suisse reduced its Myriad Genetics (MYGN) stake by 40% in Q1 2024, selling an estimated $1.39M and leaving 98,455 shares worth $2.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1827.

Credit Suisse first reported a position in MYGN in Q2 2013 and has held it in 44 quarters since. The position peaked at $11.7M in Q1 2016. 186 funds tracked by Wall St. Rank hold MYGN as of Q1 2024.

  • Credit Suisse held 98,455 shares of Myriad Genetics worth $2.1M as of Q1 2024.
  • Credit Suisse sold 64,557 Myriad Genetics shares in Q1 2024, an estimated $1.39M.
  • Myriad Genetics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1827 holding.
  • Credit Suisse first reported a position in Myriad Genetics in Q2 2013 and has held it in 44 quarters since.
  • Credit Suisse's Myriad Genetics position peaked at $11.7M in Q1 2016.
  • 186 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.